knowledge -WSS

knowledge

author：entertainment 2025-09-28 00:50:28 - browse：6

Two people in protective equipment work in a lab. — JUAN MABROMATA/AFP via Getty Images

Biosimilars are no longer a new and untested class of medicines. Today, they provide critical treatment options across multiple therapeutic areas. Since the Biologics Price Competition and Innovation Act of 2009 created a regulatory pathway for biosimilar medicine review in the U.S., 37 biosimilars have come to market offering the potential to increase patient choice and cost savings. And according to the 2023 analysis from IQVIA, biosimilars are expected to generate $181 billion in savings for the U.S. health care system over the next five years.

This progress is due, in part, to thoughtfully considered, scientifically robust regulatory standards, which have instilled confidence among health care providers and patients while protecting safety. As a former associate director of therapeutic biologics at the Food and Drug Administration, I had the privilege of helping create and lead implementation of the regulatory framework for biosimilars. The FDA took great care to apply appropriate scientific rigor to the development and approval standards. While I have since moved to Amgen, my goals have remained focused on biosimilar product quality and efficacy, patient safety, and prescriber confidence.

More than a decade later, collective efforts by biosimilar manufacturers and the FDA are paying off.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Canadians with cystic fibrosis outlive Americans by a decade

hotspot

WSS

How digital tools helped lower hypertension in marginalized patients

Industry veterans launch new biotech VC with $310M

Security flaws in third

Fatty liver disease was alleviated by Lilly’s ‘triple

Private equity deals in Medicare Advantage declines

To avoid data mishandling cases, universities eye AI and other tools

Wikipedia

knowledge

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

Key House Republican on health care plans exit from Congress

Affirmative action in medical school literally saved lives

What should King Charles tell the public about his cancer?

United colonoscopy coverage change 'may cost lives,' doctors say

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

New air purifier tech could be key to improving indoor air quality

AstraZeneca lung cancer study comes in below expectations

Heart attack and stroke risk calculators need revising

Skip the lead apron during X

focus

Undocumented workers face uncertainty as immigration law takes effect in Florida

Canadians with cystic fibrosis outlive Americans by a decade

Why did Pfizer dish out millions for a Super Bowl ad?

Why did Pfizer dish out millions for a Super Bowl ad?

A letter from the executive editor: The 2023 STATUS List

Key House Republican on health care plans exit from Congress

hotspot

focus

Wikipedia

leisure time